Duvakitug（曾用名TEV’574）是一款潜在“best-in-class”的人源IgG1-λ2单抗，靶向TL1A，又称肿瘤坏死因子（TNF）超家族成员15。TL1A通过与其受体DR3结合，可放大炎症反应并加速IBD相关纤维化的进展。靶向TL1 ...

Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

对于肠道炎症较重的活动期IBD患者，宜从少量清炖的鸡汤开始，少吃多餐，随着肠道炎症的逐渐好转，可逐渐增加鸡汤分量。缓解期IBD患者可适量多食用鸡肉性食物。无论是活动期还是缓解期，IBD患者都不能食用未熟透的煎制的鸡肉和鸡排。

As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...

Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative ...

Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most ...

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent ...

Investing.com -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)股价在宣布其用于治疗炎症性肠病 ...

Teva Pharmaceutical (NYSE: TEVA) and Sanofi (NASDAQ: SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ...

Eli Lilly LLY announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...